Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-1,2-dihydro-3-[(N-methylanilino)methyl]-pyrido[3,4-b]pyrazin-7-ylcarbamate (NSC 181928)

Ethyl 5-amino-1,2-dihydro-3-[N-methylanilino)methyl]pyrido[3,4-b]pyrazin-7-ylcarbamate (NSC 181928) is reported to be active against several experimental neoplasms. The experimental data obtained in the present study indicate that it causes the accumulation of cells at mitosis with both cultured cel...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1982-03, Vol.42 (3), p.791-798
Main Authors: Wheeler, G P, Bowdon, B J, Werline, J A, Adamson, D J, Temple, Jr, C G
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - pharmacology
Cell Division - drug effects
Cell Line
Cell Survival - drug effects
DNA - biosynthesis
Dose-Response Relationship, Drug
Drug Evaluation, Preclinical
Methotrexate - pharmacology
Mice
Mice, Inbred BALB C
Mitosis - drug effects
Neoplasm Transplantation
Neoplasms, Experimental - pathology
Pyrazines - pharmacology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ethyl 5-amino-1,2-dihydro-3-[N-methylanilino)methyl]pyrido[3,4-b]pyrazin-7-ylcarbamate (NSC 181928) is reported to be active against several experimental neoplasms. The experimental data obtained in the present study indicate that it causes the accumulation of cells at mitosis with both cultured cells and ascites cancer cells in vivo. This effect was observed with L1210, P388, colon cancer 26, colon cancer 38, and H.Ep. 2 cells in culture and with L1210 cells and P388 cells in mice. The agent was also active in vitro and in vivo against a line of leukemia P388 cells that are resistant to vincristine.
ISSN:0008-5472